goralatide has been researched along with Leukocytopenia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bogden, AE; Carde, P; Deschamps de Paillette, E; Frindel, E; Gamba-Vitalo, C; Moreau, JP; Tubiana, M | 1 |
| Guest, I; Uetrecht, J | 1 |
1 review(s) available for goralatide and Leukocytopenia
| Article | Year |
|---|---|
Bone marrow stem cell protection from chemotherapy by low--molecular-weight compounds.
Topics: Amifostine; Anemia, Aplastic; Antineoplastic Agents; Bone Marrow Cells; Ethylenes; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Leukopenia; MEDLINE; Molecular Weight; Oligopeptides; Pyrrolidonecarboxylic Acid; Thrombocytopenia | 2001 |
1 other study(ies) available for goralatide and Leukocytopenia
| Article | Year |
|---|---|
Goralatide (AcSDKP), a negative growth regulator, protects the stem cell compartment during chemotherapy, enhancing the myelopoietic response to GM-CSF.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cytarabine; Feasibility Studies; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Growth Inhibitors; Hematopoietic Stem Cells; Leukocyte Count; Leukopenia; Leukopoiesis; Mice; Oligopeptides; Platelet Count; Time Factors | 1998 |